Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
US biotech Moderna and Japan’s Mitsubishi Tanabe Pharma have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax. 9 July 2024
Biotechnology
French immuno-oncology company ImCheck Therapeutics has appointed Stephan Braun as chief medical officer. 9 July 2024
Biotechnology
US pharma major Eli Lilly is to acquire Morphic (Nasdaq: MORF), a US biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, for $3.2 billion. 8 July 2024
Biotechnology
Florida, USA-based Ligand Pharmaceuticals today announced that it has entered into a definitive agreement to acquire privately-held Austrian company Aperion Biologics. 8 July 2024
Biotechnology
Kineta saw its shares rise almost 30% to $0.79 in pre-market activity, on news that it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences. 8 July 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has announced the appointment of Paul Carter as chair of the board of directors. 8 July 2024
Biotechnology
Research news was prominent last week, first with US healthcare giant Johnson & Johnson presenting new data on nipocalimab in the treatment of generalized myasthenia gravis (MS), pitching it against argenx’ Fc Rn blocker Vyvgart. Cartesian Therapeutics also reported positive top-line results for Descartes-08 in patients with myasthenia gravis, as well as a $130 financing. However, Roche released disappointing Phase II/III clinical trial results for its tiragolumab in combination with Tecentriq for non-small cell lung cancer (NSCLC), leading the Swiss pharma giant to halt the study. On the regulatory front, Eli Lilly gained long-awaited approval from the US Food and Drug Administration for its Alzheimer’s disease drug donanemab, to be marketed by the US pharma major under the trade name Kisunla. 7 July 2024
Pharmaceutical
Michigan, USA-based pharma Esperion has entered into a Royalty Purchase Agreement with OMERS Life Sciences (OMERS). 6 July 2024
Biotechnology
The lipid-modifying agents market, which had seen a dramatic decline over the past decade, is now set for a spectacular revival, driven by the innovating therapies Leqvio (inclisiran) from Swiss pharma giant Novartis and Repatha (evolocumab) from US biotech Amgen. 5 July 2024
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), Pieris Pharmaceuticals has notified investors that Servier Laboratories is pulling the plug on the firms’ cancer collaboration. 5 July 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze